CB
CRVS icon

Commerce Bank’s Corvus Pharmaceuticals CRVS Stock Holding History

Commerce Bank’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$154K – 1320
2025
Q4 		$154K Hold
20,000
– – ﹤0.01% 1215
2025
Q3 		$147K Hold
20,000
– – ﹤0.01% 1206
2025
Q2 		$80K Hold
20,000
– – ﹤0.01% 1182
2025
Q1 		$63.6K Hold
20,000
– – ﹤0.01% 1166
2024
Q4 		$107K Hold
20,000
– – ﹤0.01% 1162
2024
Q3 		$106K Hold
20,000
– – ﹤0.01% 1206
2024
Q2 		$36.4K Hold
20,000
– – ﹤0.01% 1190
2024
Q1 		$35.6K Hold
20,000
– – ﹤0.01% 1190
2023
Q4 		$35.2K Hold
20,000
– – ﹤0.01% 1173
2023
Q3 		$29.2K Hold
20,000
– – ﹤0.01% 1138
2023
Q2 		$45.8K Hold
20,000
– – ﹤0.01% 1145
2023
Q1 		$18.2K Hold
20,000
– – ﹤0.01% 1161
2022
Q4 		$17K Buy
+20,000
New +$17.7K ﹤0.01% 1125

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Commerce Bank's CRVS Position: Q1 2026 in Review

Commerce Bank sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 20,000 shares — an estimated $154K sold.

Commerce Bank first reported a position in CRVS in Q4 2022 and held it in 13 quarters. The position peaked at $154K in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Commerce Bank reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Commerce Bank sold 20,000 Corvus Pharmaceuticals shares in Q1 2026, an estimated $154K.
  • Commerce Bank first reported a position in Corvus Pharmaceuticals in Q4 2022 and held it in 13 quarters.
  • Commerce Bank's Corvus Pharmaceuticals position peaked at $154K in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Commerce Bank's 13F filing for Q1 2026, filed 11 May 2026.